X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KB295, a novel Microbiome metabolic therapy data shows the direct effect of administering and restoring balanced SCFA production, while depleting harmful pathobionts in order to suppress inflammation and restore gut homeostasis, in mild-to-moderate ulcerative colitis.
Lead Product(s): KB295
Therapeutic Area: Gastroenterology Product Name: KB295
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Details:
KB295 and KB109 are novel, orally administered Microbiome Metabolic Therapies (MMT™) developed using Kaleido’s proprietary synthetic chemistry technology.
Lead Product(s): KB295
Therapeutic Area: Gastroenterology Product Name: KB295
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021.
Lead Product(s): KB109
Therapeutic Area: Infections and Infectious Diseases Product Name: KB109
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
In ex vivo studies, KB295 has demonstrated the ability to increase the production of short chain fatty acids and suppress the growth of inflammatory bacteria such as Enterobacteriaceae.
Lead Product(s): KB295
Therapeutic Area: Gastroenterology Product Name: KB295
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The results include details on the effects of KB174 on microbiome nitrogen metabolism in a clinical study in patients with cirrhosis, improved tolerability for KB174 relative to lactulose, as well as effects of MMTs on bacterial composition in patient samples ex vivo.
Lead Product(s): KB174
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: KB174
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The evidence supporting the role of the microbiome in viral infections is compelling, and our clinical program will evaluate the effects of KB109 in mitigating inappropriate inflammatory response to COVID-19, and potentially avoiding more serious complications.”
Lead Product(s): KB109
Therapeutic Area: Infections and Infectious Diseases Product Name: KB109
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
The net proceeds will be used to fund the existing clinical trial of KB109 in mild-to-moderate COVID-19, Phase 2 clinical trial of KB195 in urea cycle disorders, and the planned clinical study of KB295 in mild-to-moderate ulcerative colitis.
Lead Product(s): KB109
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $35.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
